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Introduction
Juvenile systemic sclerosis (jSSc) is an orphan autoim-
mune disease. Currently only retrospective data is exist-
ing regarding the organ involvement and evolvement of
the disease. Our project is the first project, where in a
prospective manner and with a protocol regarding stan-
dardized assessment of the organ systems and quality of
life in early jSSc patients are assessed.
Objectives
to learn about the evolvement of juvenile systemic
sclerosis
Methods
Patients with less than 18 months of disease duration,
after the first Non-Raynaud symptomatic, are prospec-
tively assessed, using a standardized protocol.
Results
We report the patient characteristics at time point 0, 6 and
12 months of their follow up. We present date on
25 patients. The mean follow up of the patients in the
cohort are 3.5 years. No patient died during the follow up.
Eighteen of the 25 patients were female. The mean age of
the onset of Raynaud symptomatic was 10.4 years, the
youngest patient was 2.0 years of age. The mean age at the
onset of the non-Raynaud symptomatic were 11.0 years.
19 of the 25 have diffuse subtype, 6 of them have an
overlap symptomatic, two of them associated with diffuse
subtype. ANA positive were 20, and 8 of them were anti-
Scl 70 positive. None of them was anticentromere positive
The mean modified Rodnan Skin Score was at timepoint
0, 6 and 12 month 18.1, 15.1 (n=21) and 15.1. (n=17). Ray-
naud´s Phenomen occurred in 22/25 at time point 0 and
16 of 21 at time point 6 months and 12 of 17 at 12 months.
18 of 25 of them had
capillary changes already at time point 0. 7 of them
had already ulcerations at time point zero, 9 of 21 at
month 6 and 4 of 17 at months 12. 15 of them had car-
diopulmonary involvement, at time point zero already, 9
of them had interstitial lung disease. 6 of 21 have cardi-
opulmonary involvement at month 6 and 7 of 17 at
month 12 of follow up. Two of them have renal involve-
ment at time point 0 and 3 at time point 6 and 12
months. 9 of 25 had gastrointestinal involvement, and 5
of them oesophageal involvement at time point zero, 3
from 21 at month 6 and 5 of 17 at 12 months. 22 of 25
have musculoskeletal involvement 19 of 21 at month 6
and 16 of 17 at 12 months.
Conclusion
We present the data on the first 25 prospectively assessed
patients with jSSc. The current recruitment data confirms
that pediatric patients are different from the adult patients.
There is a striking majority of diffuse patients with 76%
and overlap feutures in 24% of the patients. None of the
patients were anticentromere antibody positive. Unfortu-
nately despite the prospective data collection, we miss
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